Simulations Plus Releases ADMET Predictor™ Version 8.0

Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that it has released Version 8.0 of its best-in-class ADMET Predictor™ molecular property prediction software.

Dr. David Miller, project leader for the ADMET Predictor redesign at Simulations Plus, said: “We are excited about this new version of ADMET Predictor, which is much more than a typical upgrade. It is a complete refactoring of the code with a new look and feel, a series of new capabilities, and tighter integration with several other Simulations Plus software products. As a result of the major refactoring of the code, it has undergone the most thorough testing in our history, and is now ready for prime time. A small sample of the many enhancements includes:

  • Automatic ‘star plots’ depicting various key molecule properties at a glance
  • Expanded and more interactive graphics
  • Several features from MedChem Studio™ are now included for enhanced data mining and insight
  • Improved optional ADMET Modeler™ Module with a new, intuitive model-building workflow
  • Tight integration with our MedChem Studio, MedChem Designer™, GastroPlus™, DDDPlus™, and MembranePlus™ software products
  • More flexible licensing to enable our users to better customize installations to fit their needs.”

John DiBella, vice president for marketing and sales for Simulations Plus, added: “ADMET Predictor has been the premiere molecular property prediction software in the pharmaceutical industry, with accuracy exceeding competitors for many years. However, we had consistently received feedback from clients and prospects about the outdated interface features. Version 8.0 changes that with an improved user experience, and that, coupled with tighter integration with MedChem Studio, should lead to increased adoption of the program by medicinal chemists, which is a target market within the pharmaceutical space that we haven’t penetrated yet.”

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said, “This new version of ADMET Predictor is the result of many months of intense work by our cheminformatics and computational technologies teams. As Dr. Miller noted, the testing of this version has been extensive, necessitated by the major refactoring of the code into an all-C++ platform from the former combination of C++ with a Visual Basic user interface. Now our best-in-class predictive software is not only the most accurate property prediction software available; it is also the most productive, with features that bring information to the surface in an attractive, insightful, and intuitive way.”

About Simulations Plus, Inc.

Simulations Plus, Inc. is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Our software is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at www.simulations-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.

Contacts:

Simulations Plus Investor Relations
Ms. Renee Bouche, 661-723-7723
renee@simulations-plus.com
or
Hayden IR
Mr. Cameron Donahue, 651-653-1854
cameron@haydenir.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.